✨ Free AI Report
H. Lundbeck A/S: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research H. Lundbeck A/S
Company Research

H. Lundbeck A/S: Business Overview, Financials & Competitive Analysis

H. Lundbeck A/S scores 6/10 on the AskCyborg Cyborg Score (Solid). Specialized CNS pharma leader with demographic tailwinds and strategic brand momentum, though facing generic competition and pricing pressures that warrant cautious valuation. Lundbeck operates in a stable niche with strong strategic brands like Vyepti and Rexulti driving growth, solid financials (~$3.7B revenue), and a robust pipeline. However, portfolio dependency.

What is H. Lundbeck A/S's industry? H. Lundbeck A/S (lundbeck.com) operates in Pharmaceuticals - Specialty (CNS/Neurological Focus). AskCyborg classifies H. Lundbeck A/S under Pharmaceuticals - Specialty (CNS/Neurological Focus) in its company registry.

Lundbeck engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company ...

6/ 10Solid

Cyborg Score thesis

Specialized CNS pharma leader with demographic tailwinds and strategic brand momentum, though facing generic competition and...

Read the full analyst-debate transcript →
Industry Pharmaceuticals - Specialty (CNS/Neurological Focus)
4 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest H. Lundbeck A/S Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for H. Lundbeck A/S

AskCyborg analysts argue the bull and bear cases for H. Lundbeck A/S across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
H. Lundbeck A/S OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

H. Lundbeck A/S Overview

Pro stress-test →

Lundbeck engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company is a specialized CNS (central nervous system) pharmaceutical leader with a portfolio spanning depression, schizophrenia, epilepsy, Parkinson's disease, and migraine prevention.

Strategic Profile

Pro stress-test →

Strong growth in strategic brands and expansion into international markets positions Lundbeck to benefit from rising diagnosis and treatment rates in brain health. A maturing pipeline and capital redeployment into innovative assets underpin long-term portfolio diversification and support future revenue and margin improvement.

Competitive Landscape

Pro stress-test →

Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company competes with larger pharma players in CNS therapeutics, differentiating through specialized portfolio focus and emerging market expansion. Major competitors include Eli Lilly (Cymbalta, Prozac), Pfizer (Lyrica), Allergan (Botox for migraine), and smaller specialized CNS firms.

Industry Context

H. Lundbeck A/S operates in Pharmaceuticals - Specialty (CNS/Neurological Focus).

Key facts

Founded: 1915 · Headquarters: Copenhagen, Denmark · Employees: 5,039 · Revenue: $3.72B · Market cap: $5.95B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on H. Lundbeck A/S.

  • Strategic brand growth: Vyepti and Rexulti driving strong international expansion, particularly in Asia and emerging markets
  • Robust clinical pipeline: Multiple late-stage programs (phase 2-3) in migraine, epilepsy, and neurodegenerative disorders signal diversification beyond core depression/schizophrenia portfolio
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • Feb 2026Q4 2025 earnings call completed; strong TTM revenue of $3.72B USD
  • Dec 2025Strong growth trajectory in Vyepti and Rexulti supporting international market expansion strategy
  • +1 moreTrack every material event for H. Lundbeck A/S as it happens. Explore monitoring →
Get alerted when H. Lundbeck A/S has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

CymbaltaLeading antidepressant for depression and anxiety disorders→LyricaNeuropathic pain and epilepsy treatment→BotoxMigraine prevention and neurological treatment→Trintellix/BrintellixLundbeck's own strategic antidepressant brand→

Compare H. Lundbeck A/S with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

H. Lundbeck A/S operates in Pharmaceuticals - Specialty (CNS/Neurological Focus). See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceuticals - Specialty (CNS/Neurological Focus) research →
NEW · MCP server

Ask your AI assistant about H. Lundbeck A/S

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare H. Lundbeck A/S and its top competitor on Cyborg Score”
“What did H. Lundbeck A/S do this quarter?”
“Is H. Lundbeck A/S a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does H. Lundbeck A/S do?+
Lundbeck engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company ...
What is H. Lundbeck A/S's Cyborg Score?+
H. Lundbeck A/S has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are H. Lundbeck A/S's main competitors?+
Named competitors include Cymbalta, Lyrica, Botox, Trintellix/Brintellix. The full competitive landscape is in the AskCyborg report.
How can I get the full H. Lundbeck A/S research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the H. Lundbeck A/S research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track H. Lundbeck A/S over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.